OTCMKTS:HGEN - Humanigen Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $27.00
  • Forecasted Upside: 108.41 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$12.96
▼ -0.71 (-5.20%)
1 month | 3 months | 12 months
Get New Humanigen Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for HGEN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for HGEN

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$27.00
▲ +108.41% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Humanigen in the last 3 months. The average price target is $27.00, with a high forecast of $31.00 and a low forecast of $25.00. The average price target represents a 108.41% upside from the last price of $12.96.
Buy
The current consensus among 3 investment analysts is to buy stock in Humanigen.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/4/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/2/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/31/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/29/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/28/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/27/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/25/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/25/2020

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetDetails
10/20/2020Cantor FitzgeraldInitiated CoverageOverweight$25.00
i
10/14/2020HC WainwrightInitiated CoverageBuy$31.00
i
10/1/2020Roth CapitalInitiated CoverageBuy$25.00
i
11/19/2015Needham & Company LLCReiterated RatingHold
i
Rating by Alan Carr at Needham & Company LLC
(Data available from 10/25/2015 forward)
Humanigen logo
Humanigen, Inc., a biopharmaceutical company, engages in developing its proprietary monoclonal antibodies for immunotherapy and oncology treatments. The company's products include lenzilumab and ifabotuzumab, which are monoclonal antibodies derived from Humaneered platform. Lenzilumab targets granulocyte-macrophage colony-stimulating factor (GM-CSF), and is in development as a potential medicine for chimeric antigen receptor T cell (CAR-T) therapy, as well as a potential treatment for rare hematologic cancers, such as chronic myelomonocytic leukemia (CMML) and juvenile myelomonocytic leukemia (JMML). Ifabotuzumab targets Ephrin type-A receptor 3 (EphA3), and is being explored as a potential treatment for glioblastoma multiforme (GBM) and other cancers, as well as for use in novel CAR-T construct and bispecific antibody platform. The company was formerly known as KaloBios Pharmaceuticals, Inc. and changed its name to Humanigen, Inc. in August 2017. Humanigen, Inc. was founded in 2000 and is based in Burlingame, California.
Read More

Today's Range

Now: $12.96
$12.88
$13.42

50 Day Range

MA: $10.97
$1.99
$15.00

52 Week Range

Now: $12.96
$1.50
$33.95

Volume

380,373 shs

Average Volume

179,389 shs

Market Capitalization

$650.19 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A